Saturday, October 31, 2026

COVID-19: $1 Trillion Loss Could Set Global Tourism Industry Back 20 Years

ViaNews Editorial Team

September 5, 2020

Photo by Markus Spiske on Unsplash

The economic damage to the global tourism sector as a result of the coronavirus pandemic is likely to exceed $1 trillion this year, which would set the industry back two decades, according to a new report from the United Nations.

"Depending on when travel restrictions will be fully lifted, the World Tourism Organization expects international tourism receipts (i.e. spending by international tourists) to drop between $910 billion and $1.2 trillion this year, which would set the global tourism industry back by 20 years," UNWTO said.

The report adds that the coronavirus-related restrictions brought international travel to a crashing halt in April and May, resulting in international tourist arrivals that trailed last year's total by almost 60 percent through the first five months of 2020.

The UNWTO says the tourism sector employs one in every ten people on Earth and warns that up to 120 million direct tourism jobs are at risk.

Data from the World Travel & Tourism Council, the travel and tourism sector accounted for 10.3% of global GDP and 330 million jobs in 2019.

Read more: When Is Global Business Travel Expected to Rebound?

Road to Recovery

In a video message, UN Secretary-General António Guterres said the tourism sector must be rebuilt so that it would "regain its position as a provider of decent jobs, stable incomes, and the protection of our cultural and natural heritage."

According to him, international tourist arrivals decreased by more than half and some 320 billion dollars in exports from tourism were lost in the first five months of this year.

Guterres added that many of the jobs at risk are in the informal economy or in micro, small, and medium-sized enterprises, which employ a high proportion of women and young people.

"The crisis is a major shock for developed economies, but for developing countries, it is an emergency, particularly for many small islands developing states and African countries. For women, rural communities, indigenous peoples, and many other historically marginalized populations, tourism has been a vehicle for integration, empowerment, and generating income."

He stressed that rebuilding the industry must be done in a way that is safe, equitable and climate-friendly as "transport-related greenhouse gas emissions could rebound sharply if recovery is not aligned with climate goals".

Read more: Portugal Should Top Your Bucket List This Summer: SeaBookings’s Co-Founder

The secretary-general also noted that he has identified five priority areas to aid recovery. "First, mitigate the socio-economic impacts of the crisis. Second, build resilience across the entire tourism value chain. Third, maximize the use of technology in the tourism sector. Fourth, promote sustainability and green growth. And fifth, foster partnerships to enable tourism to further support the Sustainable Development Goals."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com